Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Alison Simmons, the Director of the Oxford University MRC Human Immunology Unit (MRC HIU), together with Dr Hashem Koohy, group leader at Radcliffe Department of Medicine and the MRC HIU, have been awarded a Chan Zuckerberg Initiative Paediatric Networks for the Human Cell Atlas grant.

Alison Simmons on left  , Hashem Koohy on right

The Chan Zuckerberg Initiative (CZI) has announced $33 million in grants to support collaborative groups of researchers and paediatricians to better understand, prevent, and treat childhood diseases.

These 17 groups of researchers represent 15 different countries, and will contribute healthy paediatric single-cell reference data to the global Human Cell Atlas as a foundational resource for providing insight into the cellular origins of disease onset in children.

Professor Simmons project aims to develop an open access spatiotemporal atlas of childhood intestinal development, with the team building a single-cell atlas of the paediatric intestine. This will help researchers and clinicians understand how the human intestine matures in childhood, as well as adult intestinal diseases.

Professor Simmons team, in collaboration with Dr Koohy’s group, has previously provided open access atlases of the human colon in health and inflammatory bowel disease (IBD), and a resource documenting how the human foetal intestine develops. These resources highlighted an urgent need to undertake studies to better understand how a healthy immune system develops in symbiosis with the intestinal microbiota, and provide a framework to understand both neonatal, childhood, and adult intestinal diseases.

Read the full story on the MRC Weatherall Institute of Molecular Medicine

Similar stories

COVID-19 increased public trust in science, new survey shows

A survey of over 2000 British adults has found that public trust in science, particularly genetics, increased significantly during the pandemic. However, those with extremely negative attitudes towards science tend to have high self-belief in their own understanding despite low textbook knowledge.

Gero Miesenböck awarded 2023 Japan Prize

Congratulations to Professor Gero Miesenböck, Department of Physiology, Anatomy and Genetics (DPAG), who has been awarded the 2023 Japan Prize in the field of Life Sciences, together with Professor Karl Deisseroth, for pioneering work in the field of optogenetics.

Major funding for Oxford will help find new cancer treatments

Cancer Research UK and the National Institute for Health and Care Research are investing over £3 million across the next five years into The University of Oxford’s Experimental Cancer Medicine Centre (ECMC). The investment will enable Oxford to expand its portfolio of precision prevention and early detection cancer trials.

Daniel Freeman to join Department of Experimental Psychology as Professor of Psychology

The Department of Experimental Psychology are delighted to announce that Daniel Freeman has been appointed as their new Professor of Psychology, joining from the Department of Psychiatry.

New study reveals role of lymphatic system in bone healing

It was previously assumed that bones lacked lymphatic vessels, but new research from the MRC Human Immunology Unit at Oxford's MRC Weatherall Institute for Molecular Medicine not only locates them within bone tissue, but demonstrates their role in bone and blood cell regeneration and reveals changes associated with aging.

Vaccination shown to protect against pregnancy complications from COVID-19 Omicron variant

The global network led by the Oxford Maternal and Perinatal Health Institute (OMPHI) at the University of Oxford has today published, in The Lancet, the results of the ‘2022 INTERCOVID Study’ conducted in 41 hospitals across 18 countries.